title: Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment.
authors.forename: Christophe
authors.initials: C
authors.lastname: Perrin
authors.forename: Cédric
authors.initials: C
authors.lastname: Fabre
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Raoul
authors.forename: Eveline
authors.initials: E
authors.lastname: Boucher
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy; D006801:Humans; D008275:Magnesium Deficiency / Q000139:chemically induced* / Q000150:complications; D008297:Male; D001523:Mental Disorders / Q000209:etiology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab